By Fineline Cube 
China Isotope & Radiation Corporation (CIRC; HKG: 1763) and Hong Kong-based Qianlong International Holdings Ltd. have entered into a strategic cooperation agreement. The collaboration aims to leverage Qianlong International’s investments in domestic cancer treatment facilities to jointly promote boron neutron capture therapy (BNCT) and other nuclear medical solutions.
Collaboration Objectives
The partnership will focus on advancing the application of BNCT, nuclear medical equipment, radiopharmaceuticals, and smart nuclear medicine solutions in both domestic and international markets. This strategic move is designed to enhance healthcare benefits through technological innovation.
R&D and Industrial Production
CIRC and Qianlong International will explore collaborative opportunities in the research and development (R&D) and industrial production of nuclear medical products, aiming to drive technological advancements and jointly develop high-end nuclear medicine industries.
Qianlong International’s Expertise
Qianlong International is a global investment firm specializing in biotechnology, digital health, and specialized nutritional products. The firm focuses on the investment and commercialization of innovative technologies, making it a valuable partner in this strategic collaboration.-Fineline Info & Tech